NDAs Get Bioequivalence Room Of Their Own In New Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft highlights bioavailability and bioequivalence concerns unique to new drugs and how they contribute to FDA’s evaluation of safety and effectiveness.